BLUE Stock Stiff: Analysis Suggests Gene Therapy Was Not Guilty Guilty
Bluebird Bio (BLUE) said on Wednesday that experimental gene therapy for blood diseases was probably not the culprit in a patient’s cancer diagnosis, which led to BLUE stock popping up. X The…
